Skip to content

8-KAccepted Nov 16, 7:09 AM ET

Prelude Therapeutics Inc: reports results for quarter ended Sep 30, 2026

PRLDPrelude Therapeutics Inc

Accepted (ET)

7:09 AM

Nov 16, 2026

Filed

Nov 16, 2026

Documents

47

Size

21.7 MB

Summary

Prelude Therapeutics Inc: reports results for quarter ended Sep 30, 2026

Updated

What happened

  • On Nov 16, 2026, Prelude Therapeutics Incorporated issued a press release announcing its financial results for the three months ended Sep 30, 2026. The press release is attached as Exhibit 99.1 to the Current Report on Form 8-K.
  • The company has prepared investor presentation materials that management intends to use in investor presentations; those materials are attached as Exhibit 99.2 to the Current Report on Form 8-K.
  • The filing states that the information in the Current Report and in Exhibits 99.1 and 99.2 is being furnished and is not being deemed “filed” for purposes of Section 18 of the Exchange Act.

Key details

  • Press release date: Nov 16, 2026.
  • Financial period covered: three months ended Sep 30, 2026.
  • Exhibits attached: Exhibit 99.1 (press release) and Exhibit 99.2 (investor presentation).
  • The report was signed by Bryant Lim, chief financial officer and chief legal officer, on Nov 16, 2026.

Why it may matter

  • Item 2.02 (results of operations and financial condition) was reported by the company via the press release announcing financial results for the three months ended Sep 30, 2026.
  • Item 7.01 (regulation FD disclosure) was reported by furnishing investor presentation materials that management intends to use in presentations.
  • This filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing